To ask the Secretary of State for Health and Social Care, what steps he is taking to expand the rollout of long-acting injectable buprenorphine (LAIB) in i) Hampshire ii) Gosport.

Local authorities are responsible for commissioning drug and alcohol treatment services according to local need, and this includes the provision of long-acting injectable buprenorphine.

From 2026/27, all drug and alcohol treatment and recovery funding will be channelled through the Public Health Grant, with ringfenced funding for drug and alcohol treatment and recovery. This is the first multi-year settlement in over a decade and provides the certainty for local government to plan and invest for the medium term. Through the ringfenced funding, Hampshire will receive £10,999,940 in 2026/27, and indicative totals of £11,223,997 and £11,442,554 for 2027/28 and 2028/29 respectively.

The Department encourages local authorities to prioritise resourcing long-acting injectable buprenorphine prescribing if current provision is not adequate and has asked to see the specific planning assumptions and ambitions set out in the treatment plans shared with the Department.

The Department supports interventions to expand the provision of long-acting injectable buprenorphine. We are currently doing more analysis to understand cost-effectiveness, developing clinical guidance, and scoping how best to expand access to long-acting injectable buprenorphine further.